270 related articles for article (PubMed ID: 19763245)
1. Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling.
Guruswamy S; Rao CV
Gene Regul Syst Bio; 2008 May; 2():163-176. PubMed ID: 19763245
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention.
Guruswamy S; Rao CV
Int J Oncol; 2009 Nov; 35(5):1037-43. PubMed ID: 19787257
[TBL] [Abstract][Full Text] [Related]
3. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Reddy BS
Environ Mol Mutagen; 2004; 44(1):26-35. PubMed ID: 15199544
[TBL] [Abstract][Full Text] [Related]
4. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
Mo H; Elson CE
Exp Biol Med (Maywood); 2004 Jul; 229(7):567-85. PubMed ID: 15229351
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide signaling in colon cancer chemoprevention.
Rao CV
Mutat Res; 2004 Nov; 555(1-2):107-19. PubMed ID: 15476855
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor.
Rao CV; Kawamori T; Hamid R; Reddy BS
Carcinogenesis; 1999 Apr; 20(4):641-4. PubMed ID: 10223193
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.
Suh JW; Choi DJ; Chang HJ; Cho YS; Youn TJ; Chae IH; Kim KI; Kim CH; Kim HS; Oh BH; Park YB
J Korean Med Sci; 2010 Jan; 25(1):16-23. PubMed ID: 20052342
[TBL] [Abstract][Full Text] [Related]
8. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
9. Statins inhibit blastocyst formation by preventing geranylgeranylation.
Alarcon VB; Marikawa Y
Mol Hum Reprod; 2016 May; 22(5):350-63. PubMed ID: 26908642
[TBL] [Abstract][Full Text] [Related]
10. The potential of statins for individualized colorectal cancer chemoprevention.
Jacobs RJ; Kodach LL; Hardwick JC
Curr Drug Targets; 2011 Dec; 12(13):1903-8. PubMed ID: 21158709
[TBL] [Abstract][Full Text] [Related]
11. Statins and protein prenylation in cancer cell biology and therapy.
Garcia-Ruiz C; Morales A; Fernandez-Checa JC
Anticancer Agents Med Chem; 2012 May; 12(4):303-15. PubMed ID: 22413970
[TBL] [Abstract][Full Text] [Related]
12. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Danesh FR; Kanwar YS
FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
[TBL] [Abstract][Full Text] [Related]
13. Molecular Targets in Precision Chemoprevention of Colorectal Cancer: An Update from Pre-Clinical to Clinical Trials.
Yarla NS; Madka V; Pathuri G; Rao CV
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348563
[TBL] [Abstract][Full Text] [Related]
14. COX-2 and iNOS, good targets for chemoprevention of colon cancer.
Watanabe K; Kawamori T; Nakatsugi S; Wakabayashi K
Biofactors; 2000; 12(1-4):129-33. PubMed ID: 11216473
[TBL] [Abstract][Full Text] [Related]
15. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory effects of HMG-CoA reductase inhibitors.
Danesh FR; Anel RL; Zeng L; Lomasney J; Sahai A; Kanwar YS
Arch Immunol Ther Exp (Warsz); 2003; 51(3):139-48. PubMed ID: 12894868
[TBL] [Abstract][Full Text] [Related]
17. Nutritional targeting of cyclooxygenase-2 for colon cancer prevention.
Romagnolo DF; Papoutsis AJ; Selmin O
Inflamm Allergy Drug Targets; 2010 Jul; 9(3):181-91. PubMed ID: 20553228
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
19. In vitro effects of active components of Polygonum Multiflorum Radix on enzymes involved in the lipid metabolism.
Wang W; He Y; Lin P; Li Y; Sun R; Gu W; Yu J; Zhao R
J Ethnopharmacol; 2014 May; 153(3):763-70. PubMed ID: 24680992
[TBL] [Abstract][Full Text] [Related]
20. Preventive potential of wheat bran fractions against experimental colon carcinogenesis: implications for human colon cancer prevention.
Reddy BS; Hirose Y; Cohen LA; Simi B; Cooma I; Rao CV
Cancer Res; 2000 Sep; 60(17):4792-7. PubMed ID: 10987288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
